WINTON GROUP Ltd Takes $340,000 Position in The Chemours Company (NYSE:CC)

WINTON GROUP Ltd bought a new stake in shares of The Chemours Company (NYSE:CC - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 20,141 shares of the specialty chemicals company's stock, valued at approximately $340,000.

A number of other hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Chemours by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,229,052 shares of the specialty chemicals company's stock valued at $24,974,000 after buying an additional 32,590 shares in the last quarter. FMR LLC raised its position in shares of Chemours by 3.5% during the third quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company's stock worth $368,650,000 after purchasing an additional 618,361 shares during the period. ARGA Investment Management LP raised its position in shares of Chemours by 61.0% during the third quarter. ARGA Investment Management LP now owns 147,582 shares of the specialty chemicals company's stock worth $2,999,000 after purchasing an additional 55,903 shares during the period. Erste Asset Management GmbH purchased a new stake in shares of Chemours during the third quarter valued at $728,000. Finally, Cinctive Capital Management LP boosted its position in shares of Chemours by 577.1% in the 3rd quarter. Cinctive Capital Management LP now owns 296,415 shares of the specialty chemicals company's stock valued at $6,023,000 after purchasing an additional 252,640 shares during the period. 76.26% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Chemours Stock Up 0.9 %

Shares of NYSE:CC traded up $0.12 during midday trading on Wednesday, hitting $13.08. 4,547,957 shares of the stock were exchanged, compared to its average volume of 1,739,897. The company has a market capitalization of $1.95 billion, a PE ratio of 22.95 and a beta of 1.84. The Chemours Company has a 52-week low of $12.69 and a 52-week high of $29.21. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The business's fifty day simple moving average is $16.15 and its two-hundred day simple moving average is $18.15.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. As a group, research analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, February 28th. This represents a $1.00 annualized dividend and a dividend yield of 7.65%. Chemours's dividend payout ratio (DPR) is 175.44%.

Analyst Upgrades and Downgrades

A number of research firms have commented on CC. BMO Capital Markets reduced their price objective on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. The Goldman Sachs Group decreased their price objective on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. Truist Financial began coverage on shares of Chemours in a research note on Tuesday, January 28th. They set a "buy" rating and a $27.00 target price on the stock. Morgan Stanley decreased their target price on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Barclays lowered their price target on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a report on Tuesday. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $22.56.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.